Malignant neoplasm of tail of pancreas
ICD-10 C25.2 is a billable code used to indicate a diagnosis of malignant neoplasm of tail of pancreas.
Malignant neoplasm of the tail of the pancreas is a type of pancreatic cancer that arises from the cells in the tail region of the pancreas. This cancer is often asymptomatic in its early stages, leading to late diagnosis when the disease is more advanced. Symptoms may include abdominal pain, weight loss, jaundice, and changes in stool. The staging of pancreatic cancer is particularly challenging due to the pancreas's deep location in the abdomen and the tendency for the cancer to metastasize early. The most common biomarker used in the diagnosis and monitoring of pancreatic cancer is CA 19-9, which can help assess treatment response and disease progression. Unfortunately, the prognosis for patients diagnosed with malignant neoplasm of the tail of the pancreas is generally poor, with a five-year survival rate often below 10%. This is primarily due to late-stage diagnosis and the aggressive nature of the disease, which often spreads to nearby organs and lymph nodes before detection.
Detailed pathology reports, imaging studies, and treatment plans must be documented.
Patients presenting with abdominal pain and weight loss, diagnosed via imaging and biopsy.
Ensure accurate staging and documentation of CA 19-9 levels for treatment monitoring.
Endoscopic findings, imaging results, and biopsy reports are essential.
Patients with obstructive jaundice or pancreatitis symptoms requiring further evaluation.
Document any endoscopic interventions and their outcomes.
Used when a patient with suspected pancreatic cancer undergoes exploratory surgery.
Document findings, any biopsies taken, and the rationale for the procedure.
Oncologists should ensure that all findings are clearly documented for staging purposes.
Common symptoms include abdominal pain, unexplained weight loss, jaundice, and changes in stool color. However, many patients may be asymptomatic in the early stages.
